Ephrati-Elizur and Zamenhof1 demonstrated that deoxyribonucleic acid from Bacillus subtilis grown in 5-bromouracil-supplemented media contained this analogue and retained its transforming activity. It thus became important to determine the specific transforming activity for purified fractions of each of the three molecular variants of deoxyribonucleic acid which can be extracted from organisms treated with 5-bromouracil : (1) unlabelled deoxyribonucleic acid molecules, and those in. which 5-bromouracil has been substituted for thymine in (2) one strand (‘unifilar’ labelling) or in (3) both strands (‘bifilar’ labelling) of the double helix. Two strains of Bacillus subtilis, wild type2 and uracil-requiring strain 265 (kindly supplied by Dr. R. Guthrie), served as the donors of deoxyribonucleic acid. These were first grown with aeration at 37° C. for 4 hr. in nutrient broth supplemented with thymidine (10 µgm. per ml.), and afterwards incubated for 2–3 generations in minimal broth2 containing 2–5 µgm. 5-fluorodeoxyuridine (serving as the thymidylic acid synthetase inhibitor3), 25 µgm. uridine (to suppress the conversion of 5-fLuorodeoxyuridine to 5-fluorouracil and 5-fluorouridine) and 50–250 µgm. 5-bromodeoxyuridine per ml. Under these conditions, similar to those first employed for Escherichia coli by Lorkiewicz and Szybalski4, the molar ratio of 5-bromouracil to 5-bromouracil + thymine (5-bromouracil substitution) in non-fractionated deoxyribonucleic acid varied from 35 to 61 per cent as assessed by Chromatographic determination5.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ephrati-Elizur, E., and Zamenhof, S., Nature, 184, 472 (1959).
Spizizen, J., Proc. U.S. Nat. Acad. Sci., 44, 1072 (1958); Fed. Proc., 18, 957 (1959).
Harbers, E., Chaudhuri, N. K., and Heidelberger, C., J. Biol. Chem., 234, 1255 (1959). Cohen, S. S., Flaks, J. G., Barner, H. D., Loeb, M. R., and Lichtenstein, J., Proc. U.S. Nat. Acad. Sci., 44, 1004 (1958).
Lorkiewicz, A., and Szybalski, W., Biochem. Biophys. Res. Comm., 2, 413 (1960).
Djordjevic, B., and Szybalski, W., J. Exp. Med., 112, 509 (1960).
Meselson, M., Stahl, F. W., and Vinograd, J., Proc. U.S. Nat. Acad. Sci., 43, 581 (1957). Meselson, M., and Stahl, F. W., ibid., 44, 671 (1958).
Szybalski, W., Experientia, 16, 164 (1960).
Szybalski, W., Opara-Kubinska, Z., and Ephrati-Elizur, E., Fed. Proc., 19, 306 (1960).
Eigner, J., Ph.D. thesis, Harvard University (1960).
Marmur, J., and Doty, P., Nature, 183, 1427 (1959).
Rolfe, R., and Meselson, M., Proc. U.S. Nat. Acad. Sci., 45, 1039 (1959).
About this article
Cite this article
SZYBALSKI, W., OPARA-KUBINSKA, Z., LORKIEWICZ, Z. et al. Transforming Activity of Deoxyribonucleic Acid labelled with 5-Bromouracil. Nature 188, 743–745 (1960). https://doi.org/10.1038/188743a0
Wacław Szybalski's contribution to immunotherapy: HGPRT mutation & HAT selection as first steps to gene therapy and hybrid techniques in mammalian cells
INCORPORATION OF 5-BROMODEOXYURIDINE AND 5-IODODEOXYURIDINE INTO VIRAL DNA AND ITS EFFECT ON THE INFECTIVE PROCESS*
Annals of the New York Academy of Sciences (2006)
Biochemical Pharmacology (1979)
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis (1966)